Otsuka Pharmaceutical: Difference between revisions
Content deleted Content added
No edit summary |
Jnana acquisition |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 58: | Line 58: | ||
==History== |
==History== |
||
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].<ref name=fujitoslodkowski2010/> The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name="fujitoslodkowski2010">{{Cite news | |
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].<ref name=fujitoslodkowski2010/> The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name="fujitoslodkowski2010">{{Cite news |last1=Fujita |first1=Junko |last2=Slodkowski |first2=Antoni |date=December 16, 2010 |title=Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 |agency=Reuters |editor-last=Layne |editor-first=Nathan |url=http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |url-status=dead |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20120304221059/http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |archive-date=March 4, 2012}}</ref> |
||
===Otsuka Pharmaceutical Co. Ltd Holdings=== |
===Otsuka Pharmaceutical Co. Ltd Holdings=== |
||
| Line 69: | Line 69: | ||
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref> |
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref> |
||
In |
In 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.<ref name=cen2023>{{cite news|url=https://cen.acs.org/business/mergers-&-acquisitions/Otsuka-buy-Mindset-Pharma/101/i30|title=Otsuka to buy Mindset Pharma|last=Howes|first=Laura|work=[[Chemical & Engineering News]]|date=September 9, 2023|access-date=June 1, 2024}}</ref> |
||
===Acquisition history=== |
===Acquisition history=== |
||
| Line 77: | Line 77: | ||
** [[Ridge Vineyards]] <small>(Acq 1986)</small><ref>{{cite web | url=https://www.otsuka.co.jp/en/company/otsuka-people-talk/13.html | title=Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk }}</ref> |
** [[Ridge Vineyards]] <small>(Acq 1986)</small><ref>{{cite web | url=https://www.otsuka.co.jp/en/company/otsuka-people-talk/13.html | title=Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk }}</ref> |
||
** [[Crystal Geyser Water Company]] <small>(Acq 1990)</small><ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive|url=https://web.archive.org/web/20190616203733/https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf |date=2019-06-16 }}, ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref> |
** [[Crystal Geyser Water Company]] <small>(Acq 1990)</small><ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive|url=https://web.archive.org/web/20190616203733/https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf |date=2019-06-16 }}, ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref> |
||
** [[Astex Pharmaceuticals]] <small>(Merged 2011, Acq 2013)</small><ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title=Japan's Otsuka to buy U.S. cancer firm Astex for $886 million| first=Tim| last=Kelly| |
** [[Astex Pharmaceuticals]] <small>(Merged 2011, Acq 2013)</small><ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title=Japan's Otsuka to buy U.S. cancer firm Astex for $886 million| first=Tim| last=Kelly| work=Reuters| date=September 5, 2013 }}</ref> |
||
*** Astex Therapeutics Limited |
*** Astex Therapeutics Limited |
||
*** SuperGen, Inc |
*** SuperGen, Inc |
||
| Line 87: | Line 87: | ||
*** Neurovance, Inc <small>(Acq 2017)</small><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref> |
*** Neurovance, Inc <small>(Acq 2017)</small><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref> |
||
*** Mindset Pharma Inc <small>(Acq 2023)</small> |
*** Mindset Pharma Inc <small>(Acq 2023)</small> |
||
*** Jnana Therapeutics Inc. <small>(Acq 2024)</small><ref>{{cite web|url=https://www.jnanatx.com/otsuka-pharmaceutical-completes-acquisition-of-jnana-therapeutics-inc/|title=Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.|website=GEN|date=23 September 2024 |access-date=2 October 2024}}</ref> |
|||
{{Tree list/end}} |
{{Tree list/end}} |
||
{{hidden end}} |
{{hidden end}} |
||
| Line 96: | Line 97: | ||
* [[Oronamin C]] |
* [[Oronamin C]] |
||
* [[Aripiprazole|Aripiprazole / Abilify]]<ref>{{cite web |title=Aripiprazole |url=http://adisinsight.springer.com/drugs/800001612 |publisher=AdisInsight |access-date=4 June 2017}}</ref><ref>{{cite book |last1=Behere |first1=Prakash B. |last2=Das |first2=Anweshak |last3=Behere |first3=Aniruddh P. |title=Clinical Psychopharmacology: An Update |date=2018 |publisher=Springer |isbn=9789811320927 |page=66 |url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref> |
* [[Aripiprazole|Aripiprazole / Abilify]]<ref>{{cite web |title=Aripiprazole |url=http://adisinsight.springer.com/drugs/800001612 |publisher=AdisInsight |access-date=4 June 2017}}</ref><ref>{{cite book |last1=Behere |first1=Prakash B. |last2=Das |first2=Anweshak |last3=Behere |first3=Aniruddh P. |title=Clinical Psychopharmacology: An Update |date=2018 |publisher=Springer |isbn=9789811320927 |page=66 |url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref> |
||
* [[Rejoyn]] |
|||
*SoyJoy |
|||
==References== |
==References== |
||
Latest revision as of 00:53, 3 October 2024
 | You can help expand this article with text translated from the corresponding article in Japanese. (March 2020) Click [show] for important translation instructions.
|
 | |
Native name | 大塚製薬株式会社 |
|---|---|
Romanized name | Ōtsuka Seiyaku Kabushiki-gaisha |
| Company type | Public KK |
| TYO: 4578 TOPIX 100 Component | |
| Industry | Pharmaceutical |
| Founded | 1921 (Founded) 1964 (Incorporated) |
| Founder | Busaburo Otsuka |
| Headquarters | , |
Number of locations | 69 |
Area served | Worldwide |
Key people | Tatsuo Higuchi (President) |
| Revenue | ¥ 1.74 trillion (2022) |
| ¥ 150.32 billion (2022) | |
| Owner | Nomura Trust and Banking investment trusts (11.43%) and investment trusts managed by other banks |
Number of employees | 5,634 (2017) |
| Parent | Otsuka Holdings Co. Ltd |
| Website | otsuka.com |
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
History
[edit]OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company.[1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]
Otsuka Pharmaceutical Co. Ltd Holdings
[edit]In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.[2]
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.[3]
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[4] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.[5]
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[6]
In 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.[7]
Acquisition history
[edit]Otsuka Pharmaceutical Acquisitions
- Otsuka Pharmaceutical Co., Ltd
- Ridge Vineyards (Acq 1986)[8]
- Crystal Geyser Water Company (Acq 1990)[9]
- Astex Pharmaceuticals (Merged 2011, Acq 2013)[10]
- Astex Therapeutics Limited
- SuperGen, Inc
- Avanir Pharmaceuticals (Acq 2014)[11]
- Daiya (Acq 2017)[12]
- ReCor Medical, Inc. (Acq 2019)[13]
- Otsuka America, Inc
Products
[edit]
References
[edit]- ^ a b Fujita, Junko; Slodkowski, Antoni (December 16, 2010). Layne, Nathan (ed.). "Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1". Reuters. Archived from the original on March 4, 2012. Retrieved January 15, 2012.
- ^ "Tokushima Vortis". 15 January 2020. Retrieved October 30, 2020.
- ^ "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A." otsuka.co.jp. May 28, 2008. Retrieved October 30, 2020.
- ^ Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead, BioSpace, January 13, 2012, archived from the original on March 3, 2016, retrieved January 15, 2012
- ^ UCB and Otsuka to focus collaboration on CNS disorders, Zenopa, January 13, 2012, retrieved January 15, 2012
- ^ "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. 3 March 2017. Retrieved 23 April 2018.
- ^ Howes, Laura (September 9, 2023). "Otsuka to buy Mindset Pharma". Chemical & Engineering News. Retrieved June 1, 2024.
- ^ "Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk".
- ^ Otsuka.com Library Archived 2019-06-16 at the Wayback Machine, Otsuka Pharmaceutical. Retrieved September 21, 2019.
- ^ Kelly, Tim (September 5, 2013). "Japan's Otsuka to buy U.S. cancer firm Astex for $886 million". Reuters.
- ^ Soble, Jonathan (2 December 2014). "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". The New York Times. Retrieved 23 April 2018.
- ^ "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka". Food Dive.
- ^ "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement". BioSpace.
- ^ "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms". July 11, 2018.
- ^ "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. 3 March 2017. Retrieved 23 April 2018.
- ^ "Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc". GEN. 23 September 2024. Retrieved 2 October 2024.
- ^ "Aripiprazole". AdisInsight. Retrieved 4 June 2017.
- ^ Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
External links
[edit]- (in Japanese) Otsuka Pharmaceutical Company, Limited.
- (in English) Otsuka Integrated Report 2017 (PDF) (Archived 2021-05-25 at the Wayback Machine)
| International | |
|---|---|
| National | |
Categories:
- TOPIX 100
- Otsuka Pharmaceutical
- Companies listed on the Tokyo Stock Exchange
- Pharmaceutical companies of Japan
- Food and drink companies of Japan
- Pharmaceutical companies established in 1964
- Manufacturing companies based in Tokyo
- Japanese brands
- 2010 initial public offerings
- Multinational companies headquartered in Japan